Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/23/2017 03/24/2017 03/27/2017 03/28/2017 03/29/2017 Date
10.75(c) 10.6(c) 10.8(c) 10.95(c) 11.125 Last
464 696 587 116 607 046 317 071 504 271 Volume
0.00% -1.40% +1.89% +1.39% +1.60% Change
More quotes
Financials ($)
Sales 2017 233 M
EBIT 2017 126 M
Net income 2017 66,8 M
Debt 2017 101 M
Yield 2017 -
Sales 2018 243 M
EBIT 2018 134 M
Net income 2018 75,1 M
Debt 2018 45,6 M
Yield 2018 -
P/E ratio 2017 9,76
P/E ratio 2018 8,25
EV / Sales2017 2,62x
EV / Sales2018 2,28x
Capitalization 509 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs in the Americas, Europe and Asia.It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic and... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
02:24p SUCAMPO PHARMACEUTICALS : Announces Webcast of Its Presentation at the 16th Annu..
03/28 Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 16th Ann..
03/15 Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Oppenhei..
03/13 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Regulation FD Disclosu..
03/13 SUCAMPO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements a..
03/08 SUCAMPO PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
03/08 SUCAMPO PHARMACEUTICALS : SCMP) Jumps on Q4 Results
03/08 SUCAMPO PHARMACEUTICALS : tops 4Q revenue forecasts
03/08 SUCAMPO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, C..
03/08 Sucampo Reports Fourth Quarter and Full Year 2016 Financial Results
More news
Sector news : Bio Therapeutic Drugs
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on SUCAMPO PHARMACEUTICALS, I 
2015The bullish trend is not over
More Strategies
Latest Tweets
03/28Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 16th Ann.. 
03/22Sucampo Pharmaceuticals (SCMP) Presents At Oppenheimer 27th Annual Healthcare.. 
03/22Sucampo Pharmaceuticals (SCMP) Presents At Oppenheimer 27th Annual Healthcare.. 
03/21Want the latest analyst ratings on $TCPI $GRH $SCMP $SCON $LEN.B? Get Them De.. 
03/20#TrendReversalUp $SCMP SUCAMPO PHARMACEUTICALS #TradeIdeas via ?  
More tweets
Qtime:24
News from SeekingAlpha
03/22 Sucampo Pharmaceuticals (SCMP) Presents At Oppenheimer 27th Annual Healthcare..
03/13 Sucampo Pharmaceuticals (SCMP) Presents At 29th Annual ROTH Conference
03/08 Sucampo Pharmaceuticals' (SCMP) CEO Peter Greenleaf on Q4 2016 Results - Earn..
03/08 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
03/08 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
Advertisement
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Technical analysis trends SUCAMPO PHARMACEU...
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 17,3 $
Spread / Average Target 58%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Daniel P. Getman Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICAL..-19.19%509
AMGEN, INC.12.65%121 301
CELGENE CORPORATION7.50%96 802
GILEAD SCIENCES, INC.-6.30%87 716
REGENERON PHARMACEUTIC..4.21%40 581
ACTELION LTD24.40%29 800
More Results